In psychedelic clinical trials, patients with a history of psychotic experiences, a psychotic disorder like schizophrenia, or a mood disorder with psychotic symptoms are typically screened out. (Other exclusion criteria – again, typically – include a diagnosis of bipolar disorder or recent suicidality.) The reason for excluding people with psychotic symptoms from trials on psychedelic-assisted therapy…
View Post
Unlike many other substances, psychedelics can create a lingering feeling of well-being, long after the altered state of consciousness has subsided. This is known as an ‘afterglow’. Drugs like cocaine, amphetamine, methamphetamine, and (for many) MDMA are associated with ‘comedowns’. When the high fades after the use of these drugs, you may be left with…
View Post
Dr Rick Strassman, currently an Adjunct Associate Professor of Psychiatry at the University of New Mexico, is one of the leading pioneers of modern psychedelic research. His studies on DMT, which took place between 1990 and 1995, broke the 20-year gap in psychedelic research. Strassman’s work on DMT, which kickstarted what has become known as…
View Post
Dr Rick Strassman, currently an Adjunct Associate Professor of Psychiatry at the University of New Mexico, is one of the leading pioneers of modern psychedelic research. His studies on DMT, which took place between 1990 and 1995, broke the 20-year gap in psychedelic research. This halting of prolific and promising inquiry was because the US…
View Post